Publications by authors named "Toko Saito"

Purpose: A comprehensive analysis of metabolites (metabolomics) has been proposed as a new strategy for analyzing liquid biopsies and has been applied to identify biomarkers predicting clinical responses or adverse events associated with specific treatments. Here, we aimed to identify metabolites associated with bortezomib (Btz)-related toxicities and response to treatment in newly diagnosed multiple myeloma (MM).

Methods: Fifty-four plasma samples from transplant-ineligible MM patients enrolled in a randomized phase II study comparing two less-intensive regimens of melphalan, prednisolone and Btz (MPB) were subjected to the lipidomic profiling analysis.

View Article and Find Full Text PDF
Article Synopsis
  • A study called JCOG1305 tested a new way to treat young people with advanced classic Hodgkin lymphoma (cHL) using a special PET scan after two treatment cycles.
  • Patients aged 16-60 received specific chemotherapy and then their PET scans determined if they continued the same treatment or switched to a stronger one.
  • The results showed that most patients had a good chance of staying cancer-free for at least two years, making the PET-guided treatment a promising option for younger patients with this type of cancer.
View Article and Find Full Text PDF

Objective: This phase II clinical trial evaluated feasibility and tolerability of 90-minute rituximab infusion and a concentration of 4 mg/mL rituximab infusion in Japanese patients with previously untreated follicular lymphoma or diffuse large B-cell lymphoma.

Methods: Treatment was rituximab with cyclophosphamide, doxorubicin, vincristine and prednisolone. In cycle 1, rituximab at a dose of 375 mg/m2 (4 mg/mL) was administered at the standard infusion rate stipulated in the package insert.

View Article and Find Full Text PDF
Article Synopsis
  • Despite initial therapy success, most patients with mantle cell lymphoma (MCL) eventually face relapsed or refractory (R/R) disease, prompting a study on the combination of ibrutinib and venetoclax for treatment.
  • In a Phase 2 study involving 13 patients (average age 71), the combination therapy showed an 83% complete response rate and no dose-limiting toxicities or severe treatment-related deaths after 9.6 months of follow-up.
  • The results indicate that this treatment combination is both effective and well-tolerated, offering a promising option for Japanese patients dealing with R/R MCL.*
View Article and Find Full Text PDF

Background: No consensus has been reached yet concerning treatment strategies for a sequential classic Hodgkin lymphoma (CHL) following gray zone lymphoma (GZL). Prognosis of GZL after a failed autologous hematopoietic stem-cell transplantation (auto-HCT) is poor and treatment strategy is very limited. As yet there are limited data showing clinical outcomes of brentuximab vedotin (BV) for GZL, especially for sequential CHL after GZL.

View Article and Find Full Text PDF

Objectives: Immunophenotype is an important prognostic factor for childhood and adult T-cell acute lymphoblastic leukemia. However, immunophenotypic data from adult patients with T-cell lymphoblastic lymphoma (T-LBL) are scarcely available.

Methods: Subjects were unselected adult patients with T-LBL who were treated with intensive chemotherapy.

View Article and Find Full Text PDF

There are few effective options for salvage therapy in elderly patients with relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL). The anti-CCR4 antibody mogamulizumab works via antibody-dependent cytotoxic activity, reduces regulatory T cells, and evokes antitumor immunity in cancer patients. We report a 78-year-old patient with refractory AITL receiving a new immunochemotherapy consisting of sequential mogamulizumab administration followed by the GDP (gemcitabine, dexamethasone and cisplatin) regimen.

View Article and Find Full Text PDF

Risk stratification of patients with relapsed and refractory follicular lymphoma (FL) remains challenging. Recently, much attention has been paid to the impact of early progression of disease within 2 years of diagnosis (early POD) on subsequent survival. The aim of this study was to clarify the clinical features and prognostic factors of patients with FL who experienced early POD.

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Toko Saito"

  • - Toko Saito's recent research primarily focuses on innovative treatment strategies for various types of lymphomas, emphasizing tailored approaches based on patient response and specific lymphoma characteristics.
  • - Key findings from a significant study (JCOG1305) indicate that interim PET-guided therapy can effectively stratify treatment for advanced-stage classic Hodgkin lymphoma, improving outcomes based on early scan results.
  • - Additional research highlights the feasibility of a 90-minute rituximab infusion for B-cell lymphoma and the promising combination of ibrutinib and venetoclax for patients with relapsed mantle cell lymphoma, suggesting advancements in treatment methodologies for challenging cases.

A PHP Error was encountered

Severity: Warning

Message: fopen(/var/lib/php/sessions/ci_sessionvdqa1kjop7c16k0v42s57t79m9vaki6v): Failed to open stream: No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 177

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)

Filename: Session/Session.php

Line Number: 137

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once